Figure 1.
Figure 1. Ex vivo-expanded T cells used for treatment contain tumor antigen-specific clones with late-stage effector phenotype. (A) Tumor antigen-specific CD8+ T cells are detectable in TIL samples using MART-1:26-35(27L) peptide containing HLA-A*0201 tetramer complexes and anti-CD8α antibody. Alternatively, melanoma antigen-specific T-cell clones were identified in patients 9 and 21 TIL using Vβ7- or Vβ22-specific antibodies, respectively. (B) Cell surface expression of costimulatory, lymphoid-homing, and homeostasis-associated molecules on pretreatment PBL and TIL-derived tumor antigen-specific CD8+ T cells prior to ACT. The percentage of marker-positive events within the gated tetramer or Vβ-stained, CD8α+ population are provided. Pt indicates patient; ND, not done.

Ex vivo-expanded T cells used for treatment contain tumor antigen-specific clones with late-stage effector phenotype. (A) Tumor antigen-specific CD8+ T cells are detectable in TIL samples using MART-1:26-35(27L) peptide containing HLA-A*0201 tetramer complexes and anti-CD8α antibody. Alternatively, melanoma antigen-specific T-cell clones were identified in patients 9 and 21 TIL using Vβ7- or Vβ22-specific antibodies, respectively. (B) Cell surface expression of costimulatory, lymphoid-homing, and homeostasis-associated molecules on pretreatment PBL and TIL-derived tumor antigen-specific CD8+ T cells prior to ACT. The percentage of marker-positive events within the gated tetramer or Vβ-stained, CD8α+ population are provided. Pt indicates patient; ND, not done.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal